Executive Summary
The Global Multiple Sclerosis Market is estimated at USD 26.01 Billion in the year 2020. The introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global multiple sclerosis market. Various technological advancements, such as the development of innovative monoclonal bodies, immuno-modulators, immunosuppressants and interferons for the effective treatment of MS, are acting as major growth-inducing factors. Moreover, the growth of the global multiple sclerosis market is driven by a shift in preference toward oral drugs. Also, an increase in the number of pipeline drugs is anticipated to offer lucrative opportunities for market expansion during the forecast period.
The expansion of the Multiple Sclerosis Market is encouraged by government and non-government organizations. The government and non-governmental organizations support a variety of initiatives and programs to help persons with multiple sclerosis improve their quality of life (MS).
The global multiple sclerosis market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment of this immune disorder. In addition, clinical studies for the treatment of multiple sclerosis are being conducted by several pharmaceutical companies. Companies are working to create novel medicines in multiple sclerosis radiology for patients suffering from the condition which is further driving the growth of the market.
Scope of the Report
- The report analyses the Multiple Sclerosis Market for the historical period 2016-2020 and the forecast period of 2021-2026.
- The report analyses the Multiple Sclerosis Market by Value (USD Million).
- The report analyses the Multiple Sclerosis Market Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others).
- The report analyses the Multiple Sclerosis Market by Route of Administration (Oral, Injectable, Intravenous).
- The report analyses the Multiple Sclerosis Market Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
- The Global The report analyses the Multiple Sclerosis Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
- Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA) By Country (United States, Canada, Germany, U.K, France, Italy, China, Japan, India, South Korea).
- The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by Drug Class, by Route of Administration, by Distribution Channel.
- Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, Pipelines and new product development. The companies analysed in the report include Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Pfizer Inc., GlaxoSmithKline, Novartis AG, Teva Pharmaceuticals Industries Limited, BAYER AG, Biogen, EMD Sereno, NervGen Pharma.
Key Target Audience
- Healthcare and Pharmaceutical Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
Global Multiple Sclerosis (MS) Market - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)
Table of Contents
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Multiple Sclerosis Market: Product Outlook
4. Global Multiple Sclerosis Market: Sizing and Forecast
4.1 Global Multiple Sclerosis Market Size, By Value, 2016-2026
4.2 Impact of COVID-19 on Global Multiple Sclerosis Market
5. Global Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel
5.1 Competitive Scenario of Global Multiple Sclerosis Market: By Drug Class
5.1.1 Immunomodulators - Market Size and Forecast (2016-2026)
5.1.2 Immunosuppressants - Market Size and Forecast (2016-2026)
5.1.3 Interferons - Market Size and Forecast (2016-2026)
5.1.4 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Multiple Sclerosis Market: By Route of Administration
5.2.1 Oral - Market Size and Forecast (2016-2026)
5.2.2 Injectable - Market Size and Forecast (2016-2026)
5.2.3 Intravenous - Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Multiple Sclerosis Market: By Distribution Channel
5.3.1 Hospitals Pharmacy- Market Size and Forecast (2016-2026)
5.3.2 Retail Pharmacy - Market Size and Forecast (2016-2026)
5.3.3 Online Pharmacy - Market Size and Forecast (2016-2026)
6. Global Multiple Sclerosis Market: Regional Analysis
6.1 Competitive Scenario of Global Multiple Sclerosis Market: By Region
7. North America Multiple Sclerosis Market: An Analysis (2016-2026)
7.1 North America Multiple Sclerosis Market: Size and Forecast (2016-2026)
7.2 North America Multiple Sclerosis Market - Prominent Companies
7.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
7.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
7.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
7.6 North America Multiple Sclerosis Market: Country Analysis
7.7 Market Opportunity Chart of North America Multiple Sclerosis Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Multiple Sclerosis Market: By Country
7.9 United States Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
7.10 United States Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
7.11 Canada Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
7.12 Canada Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8. Europe Multiple Sclerosis Market: An Analysis (2016-2026)
8.1 Europe Multiple Sclerosis Market: Size and Forecast (2016-2026)
8.2 Europe Multiple Sclerosis Market - Prominent Companies
8.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
8.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
8.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
8.6 Europe Multiple Sclerosis Market: Country Analysis
8.7 Market Opportunity Chart of Europe Multiple Sclerosis Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Multiple Sclerosis Market: By Country
8.9 Germany Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.10 Germany Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.11 United Kingdom Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.13 France Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.14 France Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.15 Italy Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.16 Italy Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9. Asia Pacific Multiple Sclerosis Market: An Analysis (2016-2026)
9.1 Asia Pacific Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Multiple Sclerosis Market - Prominent Companies
9.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
9.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
9.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
9.6 Asia Pacific Multiple Sclerosis Market: Country Analysis
9.7 Market Opportunity Chart Asia Pacific Multiple Sclerosis Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Multiple Sclerosis Market: By Country
9.9 China Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.10 China Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
911 Japan Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.12 Japan Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9.13 India Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.14 India Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9.15 South Korea Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.16 South Korea Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
10. Global Multiple Sclerosis Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Drug Class, 2026
11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Route of Administration, 2026
11.2 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Distribution Channel, 2026
11.3 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Region, 2026
12. Competitive Landscape
12.1 Product Pipeline of Leading Multiple Sclerosis Companies
12.2 Market Share Analysis
13. Company Analysis
13.1 Bristol-Myers Squibb
13.2 F. Hoffman-La Roche, Ltd.
13.3 Pfizer Inc.
13.4 GlaxoSmithKline
13.5 Novartis AG
13.6 Teva Pharmaceuticals Industries Limited
13.7 BAYER AG
13.8 Biogen
13.9 EMD Sereno
13.10 NervGen Pharma
List of Figures
Figure 1: Global Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 3: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 7: Global Multiple Sclerosis Market- By Drug Class Market Share, 2020 & 2026
Figure 8: Global Multiple Sclerosis Market- By Immunomodulators, By Value (USD Million), 2016-2026
Figure 9: Global Multiple Sclerosis Market- By Immunosuppressants, By Value (USD Million), 2016-2026
Figure 10: Global Multiple Sclerosis Market- By Interferons, By Value (USD Million), 2016-2026
Figure 11: Global Multiple Sclerosis Market- By Others, By Value (USD Million), 2016-2026
Figure 12: Global Multiple Sclerosis Market- By Route of Administration Market Share, 2020 & 2026
Figure 13: Global Multiple Sclerosis Market- By Oral, By Value (USD Million), 2016-2026
Figure 14: Global Multiple Sclerosis Market- By Injectable, By Value (USD Million), 2016-2026
Figure 15: Global Multiple Sclerosis Market- By Intravenous, By Value (USD Million), 2016-2026
Figure 16: Global Multiple Sclerosis Market- By Distribution Channel Market Share, 2020 & 2026
Figure 17: Global Multiple Sclerosis Market- By Hospital Pharmacy, By Value (USD Million), 2016-2026
Figure 18: Global Multiple Sclerosis Market- By Retail Pharmacy, By Value (USD Million), 2016-2026
Figure 19: Global Multiple Sclerosis Market- By Online Pharmacy, By Value (USD Million), 2016-2026
Figure 20: Global Multiple Sclerosis Market- By Region Market Share, 2020 & 2026
Figure 21: North America Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 22: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 23: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 24: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 25: North America Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 26: North America Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 27: North America Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 28: Market Opportunity Chart of North America Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)
Figure 29: North America Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
Figure 30: United States Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 31: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 32: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 33: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 34: United States Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 35: United States Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 36: United States Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 37: Canada Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 38: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 39: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 40: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 41: Canada Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 42: Canada Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 43: Canada Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 44: Europe Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 45: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 46: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 47: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 48: Europe Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 49: Europe Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 50: Europe Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 51: Market Opportunity Chart of Europe Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)
Figure 52: Europe Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
Figure 53: Germany Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 54: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 55: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 56: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 57: Germany Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 58: Germany Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 59: Germany Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 60: United Kingdom Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 61: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 62: United Kingdom Number of people with MS (per 100,000 people), 2017
Figure 63: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 64: United Kingdom Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 65: United Kingdom Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 66: United Kingdom Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 67: France Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 68: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 69: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 70: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 71: France Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 72: France Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 73: France Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 74: Italy Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 75: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 76: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 77: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 78: Italy Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 79: Italy Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 80: Italy Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 81: Asia Pacific Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 82: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 83: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 84: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 85: Asia Pacific Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 86: Asia Pacific Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 87: Asia Pacific Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 88: Market Opportunity Chart of APAC Multiple Sclerosis Market- By Country, By Value (Year-2026)
Figure 89: APAC Multiple Sclerosis Market- By Country Market Share, 2020 & 2026
Figure 90: China Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 91: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 92: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 93: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 94: China Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 95: China Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 96: China Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 97: Japan Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 98: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 99: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 100: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 101: Japan Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 102: Japan Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 103: Japan Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 104: India Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 105: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 106: e-pharmacy market in India (USD million)
Figure 107: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 108: India Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 109: India Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 110: India Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 111: South Korea Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)
Figure 112: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 113: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 114: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 115: South Korea Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 116: South Korea Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026
Figure 117: South Korea Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 118: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Drug Class (Year-2016-2026)
Figure 119: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Route of Administration (Year 2016-2026)
Figure 120: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Distribution Channel (Year 2016-2026)
Figure 121: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Region (Year 2016-2026)
Figure 122: Global Multiple Sclerosis company market share (%), 2020
Figure 123: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 124: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 125: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 126: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
Figure 127: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 128: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 129: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 130: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 131: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Figure 132: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Figure 133: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
Figure 134: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 135: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
Figure 136: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 137: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 138: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 139: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 140: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 141: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 142: Teva Pharmaceutical Industries Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 143: Teva Pharmaceutical Industries Ltd. Net Income, 2016-2020 (USD Million)
Figure 144: Teva Pharmaceutical Industries Ltd. sales Revenues, By Business Segment (%) in North America, FY2020
Figure 145: Teva Pharmaceutical Industries Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 146: Bayer Group Sales Revenues, 2016-2020 (USD Million)
Figure 147: Bayer Group Net Profit, 2016-2020 (USD Million)
Figure 148: Bayer Group, By Business Segment (%), FY2020
Figure 149: Bayer Group, By Geographical Segment (%), FY2020
Figure 150: Biogen Sales Revenues, 2016-2020 (USD Million)
Figure 151: Biogen Net Profit, 2016-2020 (USD Million)
Figure 152: Biogen, By Business Segment (%), FY2020
Figure 153: Biogen, By Geographical Segment (%), FY2020
List of Tables
Table A Product Pipeline of Leading Multiple Sclerosis Companies
Table B Product Pipeline of Leading Multiple Sclerosis Companies
Table C Product Pipeline of Leading Multiple Sclerosis Companies - NervGen Pharma
Global Fingolimod Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 74
The global Fingolimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
Global Multiple Sclerosis Drugs Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 78
The Multiple Sclerosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Sclerosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provi......
Global Multiple Sclerosis Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 21-Dec-2023 Price: US 3380 Onwards Pages: 118
Market Overview of Global Multiple Sclerosis market:
According to our latest research, the global Multiple Sclerosis market looks promising in the next 5 years. As of 2022, the global Multiple Sclerosis market was estimated at USD 13809.22 million, and it's anticipated to reach USD 21672.55 million in 2028, with a CAGR of 7.8% during the forecast years.
Multiple sclerosis (MS) is a chronic inflammatory neuropathy characterized by demyelination, axonal transection, and neurode......
Fingolimod - Global Market Insights and Sales Trends 2024
Published: 21-Dec-2023 Price: US 3350 Onwards Pages: 77
The global Fingolimod market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Fingolimod in various end use industries. The expanding demands from the Medical Field, Science Research Field and Other Fields,, are propelling Fingolimod market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Inj......
Global Fingolimod Market Research Report 2023, Forecast to 2028
Published: 19-Dec-2023 Price: US 2680 Onwards Pages: 133
Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......
Global Fingolimod Professional Survey Report 2023, Forecast to 2028
Published: 19-Dec-2023 Price: US 3280 Onwards Pages: 101
Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......
Multiple Sclerosis Drugs - Global Market Insights and Sales Trends 2024
Published: 19-Dec-2023 Price: US 3350 Onwards Pages: 96
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Multiple Sclerosis Drugs, with both qu......
Global Multiple Sclerosis Drugs Market Research Report 2023
Published: 25-Oct-2023 Price: US 2900 Onwards Pages: 87
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Multiple Sclerosis Drugs market with multiple angles, which provides sufficient supports to readers' strategy and decision making.
By Company
- Biogen
- Sanofi
- Novartis
- Teva
- Merck KGaA
- Bayer
- ACORDA
- Mallinckrodt
Segment by Type
- Injectable......
Global Multiple Sclerosis Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028
Published: 13-Jun-2023 Price: US 3260 Onwards Pages: 122
Multiple sclerosis (MS) is the most common disabling neurological disease in young people worldwide.
The Multiple Sclerosis Drugs market revenue was 15099.44 Million USD in 2022, and will reach 23584.78 Million USD in 2028, with a CAGR of 7.72% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Multiple Sclerosis Drugs industry, and breaks down according to the type, application, and consumption area of Multiple Sclero......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
